Tamsulosin (Flomax) in Benign Prostatic Hyperplasia: Evidence‑Based Recommendations

Mechanism of Action

Tamsulosin selectively blocks α₁A and α₁D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck, which improves urinary flow and reduces lower urinary tract symptoms. 1, 2, 3

The 2023 European Association of Urology (EAU) guidelines recommend tamsulosin as a first‑line oral therapy for adult men with moderate‑to‑severe LUTS/BPH, reflecting a strong recommendation based on high‑quality evidence. 1, 2, 3

Clinical trials demonstrate that tamsulosin monotherapy is effective in improving urinary symptoms across patient subgroups with varying baseline LUTS severity, supporting its broad applicability. 1, 2, 3

When combined with the 5‑α‑reductase inhibitor dutasteride, tamsulosin provides sustained clinical improvement over 2–4 years in men with symptomatic BPH and prostate enlargement, indicating additive long‑term benefit. 1, 2, 3

The 2021 AUA guidelines advise initiating an oral α‑blocker such as tamsulosin for at least 3 days before attempting a voiding trial in patients experiencing acute urinary retention secondary to BPH, to increase the likelihood of successful catheter removal. 4

Tamsulosin use is associated with intraoperative floppy iris syndrome during cataract surgery; ophthalmologists should be informed of a patient’s tamsulosin therapy before any ocular procedure to mitigate surgical complications. 1, 2, 3

In men with benign prostatic hyperplasia, stopping tamsulosin allows lower urinary tract symptoms to recur, which can cause bladder overdistension and increased intravesical pressure, leading to adverse effects on the upper urinary tract (e.g., hydronephrosis)【5】.
Chronic bladder outlet obstruction resulting from untreated BPH may produce sustained elevated bladder pressures that are transmitted to the kidneys, causing hydronephrosis and progressive renal impairment【5】.